Verdiva Bio
Gina Zang-Rosetti is an accomplished professional in the biopharmaceutical manufacturing sector, currently serving as Vice President of Manufacturing at Verdiva Bio since November 2024. Previously, Gina held the same title at Aiolos Bio from November 2023 to January 2025. A significant portion of Gina's career was spent at Genentech, where roles included Site Head for South San Francisco Production, Executive Director of Facilities & Engineering, Associate Director of Validation Engineering, and various managerial positions, starting from Manufacturing Technical Specialist to Research Associate. Gina began a career in the field at Merck & Co as a Research Associate from June 2001 to July 2004. Gina holds a Bachelor of Science degree in Biology from Lehigh University, obtained between 1997 and 2001.
This person is not in any teams
This person is not in any offices
Verdiva Bio
1 followers
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.